While 2025 is expected, and has been, a bad year for Evolent Heath 
EVH , the growth prospects look very, very promising. However, I will caution that the price could almost be cut in half from its current trading value ($9.45) with another poor earnings in 2025. This definitely isn't an "it's only up from here" stock. The price entered my "crash" simple moving area (green lines) twice and a third time could occur before the end of the year ($4-$5 range as of this writeup).
Regardless of bottom predictions, earnings forEVH are expected to rise from $1.9 billion in 2025 to $3.2 billion in 2028. EPS predicted to rise from $0.26 in 2025 to $1.18 in 2028. Debt-to-equity = 1.2x (okay, below 1 is best), Quick Ratio, or the ability to pays current bills is = 1x (okay, between 1.5 and 3 is best), and bankruptcy risk is relatively high (but reduced interest rates may help). Insiders have purchased over $11 million in shares this year with a cost average (~$23): much higher than it's current trading price.
So, while it seems there could be some short-term risks for Evolent Health, the future beyond 2025 is bright (based on company projections). Thus, at $9.45,EVH is in a personal buy zone with potential downside risk near $4-5 in the near-term.
Targets into 2028:
EVH , the growth prospects look very, very promising. However, I will caution that the price could almost be cut in half from its current trading value ($9.45) with another poor earnings in 2025. This definitely isn't an "it's only up from here" stock. The price entered my "crash" simple moving area (green lines) twice and a third time could occur before the end of the year ($4-$5 range as of this writeup). Regardless of bottom predictions, earnings for
EVH are expected to rise from $1.9 billion in 2025 to $3.2 billion in 2028. EPS predicted to rise from $0.26 in 2025 to $1.18 in 2028. Debt-to-equity = 1.2x (okay, below 1 is best), Quick Ratio, or the ability to pays current bills is = 1x (okay, between 1.5 and 3 is best), and bankruptcy risk is relatively high (but reduced interest rates may help). Insiders have purchased over $11 million in shares this year with a cost average (~$23): much higher than it's current trading price. So, while it seems there could be some short-term risks for Evolent Health, the future beyond 2025 is bright (based on company projections). Thus, at $9.45,
EVH is in a personal buy zone with potential downside risk near $4-5 in the near-term.Targets into 2028:
- $15.00 (+58.7%)
- $20.00 (+111.6%)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.